Siemens Healthineers focuses on advancing personalized cancer care through innovative technologies in theranostics, which combines diagnostics and therapeutics to tailor treatment for individual patients. Their offerings include advanced imaging systems such as the Biograph PET/CT scanners and the Biograph mMR, which enhance the detection and delineation of small lesions, thereby improving diagnostic confidence. The integration of molecular imaging technologies, such as PSMA-targeted radioligand therapies, exemplifies their commitment to precision oncology, allowing for personalized treatment plans that can significantly improve patient outcomes. Additionally, their ARIA Systemic Therapy Management system standardizes patient care across healthcare organizations, ensuring high-quality treatment pathways.

In the realm of Alzheimer's disease management, Siemens Healthineers provides a comprehensive portfolio aimed at navigating the complexities of patient care. Their digital solutions enhance workforce productivity in radiology, addressing challenges such as staff shortages through automation and remote services. The introduction of self-driving mobile C-arms, like the CIARTIC Move, exemplifies their innovative approach to medical imaging, allowing for greater flexibility and efficiency in clinical settings. Furthermore, their focus on integrating artificial intelligence into healthcare processes aims to optimize workflows and improve clinical outcomes, ultimately transforming the system of care to enhance health equity and access for all patients.

United States

Siemens Healthineersenables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare.COVID-19: CE mark for its molecular Fast Track Diagnostics (FTD)SARS-CoV-2 Assay.

Siemens Healthineers (Siemans Healthcare Diagnostics)

Company Details